A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in glioma.

Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M.

Open source

DOI
10.1038/s41598-025-21064-9
Published
2025-10-23
Container
Sci Rep
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-025-21064-9,
  title = {A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8\<sup\>+\</sup\> infiltration in glioma.},
  author = {Singh K and  Foster MW and  Violette MJ and  Corcoran AM and  Hotchkiss KM and  Railton CO and  Blandford EE and  Blethen KE and  Thomas EL and  McIntosh WC and  Ashley DM and  Desjardins A and  Friedman HS and  Johnson MO and  Friedman A and  Keir S and  Buckley ED and  Herndon JE and  McLendon RE and  Sampson JH and  Calabrese E and  López GY and  Grant GA and  Patel AP and  Gregory SG and  Li CY and  Fecci PE and  Khasraw M.},
  year = {2025},
  journal = {Sci Rep},
  doi = {10.1038/s41598-025-21064-9},
  url = {https://doi.org/10.1038/s41598-025-21064-9}
}

RIS

TY  - JOUR
TI  - A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in glioma.
AU  - Singh K
AU  -  Foster MW
AU  -  Violette MJ
AU  -  Corcoran AM
AU  -  Hotchkiss KM
AU  -  Railton CO
AU  -  Blandford EE
AU  -  Blethen KE
AU  -  Thomas EL
AU  -  McIntosh WC
AU  -  Ashley DM
AU  -  Desjardins A
AU  -  Friedman HS
AU  -  Johnson MO
AU  -  Friedman A
AU  -  Keir S
AU  -  Buckley ED
AU  -  Herndon JE
AU  -  McLendon RE
AU  -  Sampson JH
AU  -  Calabrese E
AU  -  López GY
AU  -  Grant GA
AU  -  Patel AP
AU  -  Gregory SG
AU  -  Li CY
AU  -  Fecci PE
AU  -  Khasraw M.
PY  - 2025
JO  - Sci Rep
DO  - 10.1038/s41598-025-21064-9
UR  - https://doi.org/10.1038/s41598-025-21064-9
ER  -

APA

K, S., MW, F., MJ, V., AM, C., KM, H., CO, R., EE, B., KE, B., EL, T., WC, M., DM, A., A, D., HS, F., MO, J., A, F., S, K., ED, B., JE, H., RE, M., JH, S., E, C., GY, L., GA, G., AP, P., SG, G., CY, L., PE, F., & M., K. (2025). A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8<sup>+</sup> infiltration in glioma.. Sci Rep. https://doi.org/10.1038/s41598-025-21064-9

Source records